We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

30 hedge funds and large institutions have $4.69M invested in Cellectar Biosciences in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

7% more capital invested

Capital invested by funds: $4.38M → $4.69M (+$313K)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

27% less funds holding

Funds holding: 41 → 30 (-11)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
30
Holders Change
-11
Holders Change %
-26.83%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
6
Reduced
4
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$549K
2
WVP
Worth Venture Partners
New Jersey
+$147K
3
1WM
1900 Wealth Management
Texas
+$35K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.38K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.03K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$162K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$121K
3
Citadel Advisors
Citadel Advisors
Florida
-$109K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$62.1K
5
Two Sigma Investments
Two Sigma Investments
New York
-$43K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.26M +$549K +3,134 +105%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.21M -$121K -692 -11%
BlackRock
3
BlackRock
New York
$489K -$4.03K -23 -1%
WVP
4
Worth Venture Partners
New Jersey
$315K +$147K +841 +123%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$303K – – –
MS
6
Maven Securities
Jersey
$275K – – –
ACM
7
ACT Capital Management
Pennsylvania
$150K – – –
State Street
8
State Street
Massachusetts
$103K – – –
Franklin Resources
9
Franklin Resources
California
$98K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$87K +$4.03K +23 +6%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$84K – – –
1WM
12
1900 Wealth Management
Texas
$83K +$35K +200 +100%
Northern Trust
13
Northern Trust
Illinois
$66K – – –
CAM
14
Cozad Asset Management
Illinois
$39K – – –
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$25K – – –
SCM
16
Sterneck Capital Management
Missouri
$21K – – –
MWM
17
Modera Wealth Management
New Jersey
$14K – – –
UBS Group
18
UBS Group
Switzerland
$11K -$20.7K -118 -68%
CB
19
Commerce Bank
Missouri
$10K – – –
PFS
20
Prospera Financial Services
Texas
$9K – – –
SC
21
Scotia Capital
Ontario, Canada
$8K +$175 +1 +3%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$7K -$62.1K -355 -91%
DCM
23
Difesa Capital Management
New York
$7K – – –
TRCT
24
Tower Research Capital (TRC)
New York
$6K +$4.38K +25 +833%
JFGIW
25
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$4K – – –
1
2

CLRB Hedge Fund Activity: Q1 2022 in Review

30 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2022, worth a combined $4.69M — up 7.2% from $4.38M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CLRB and 0 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 6 added.

The largest buyer was AIGH Capital Management, adding an estimated $549K. The largest seller was Morgan Stanley, exiting entirely with an estimated $162K sold.

  • 30 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2022, down from 41 in Q4 2021.
  • Funds reported $4.69M of Cellectar Biosciences stock for Q1 2022, up 7.2% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences positions in Q1 2022 and 10 closed out, a net change of -10 holders.
  • The largest Cellectar Biosciences buyer in Q1 2022 was AIGH Capital Management, an estimated $549K added.
  • The largest Cellectar Biosciences seller in Q1 2022 was Morgan Stanley, an estimated $162K sold.

Based on aggregated 13F filings for Q1 2022.